SCHEMBL266248

SCHEMBL266248

CC(=O)CCc1ccccc1C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
MAOB P27338 2/20 0.50
LMNA P02545 1/20 0.50
MAOA P21397 1/20 0.50
IAPP P10997 1/20 0.50
POLQ O75417 1/20 0.49
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
CNR1 P21554 1/20 0.46
GAA P10253 2/20 0.45
POLB P06746 1/20 0.45
EPHX2 P34913 2/20 0.45
IDO1 P14902 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
DAO P14920 1/20 0.44
FFAR1 O14842 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30257708 1.00 ALDH1A1 (0.50) ALDH1A1MAOBLMNAMAOAIAPP
SCHEMBL6286074 0.90 MAOB (0.46) ALDH1A1MAOBLMNAMAOAIAPP
SCHEMBL27872108 0.85 IDO1 (0.47) ALDH1A1MAOBMAOAPOLQHDAC1
SCHEMBL7400128 0.85 HDAC1 (0.50) ALDH1A1MAOBLMNAMAOAPOLQ
SCHEMBL15932777 0.85 IAPP (0.50) ALDH1A1MAOBLMNAMAOAIAPP
SCHEMBL29733422 0.84 EPHX2 (0.59) ALDH1A1POLQHDAC1HDAC8CNR1
SCHEMBL1953231 0.84 EPHX2 (0.59) ALDH1A1POLQHDAC1HDAC8CNR1
SCHEMBL23662783 0.83 IAPP (0.53) ALDH1A1MAOBMAOAIAPPPOLQ
SCHEMBL21576141 0.83 POLQ (0.47) ALDH1A1MAOBMAOAPOLQHDAC1
SCHEMBL3233422 0.82 MAOB (0.50) ALDH1A1MAOBMAOAPOLQHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793823-B2 Compounds and pharmaceutical uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-10-24 US disclosed
US-11793823-B2 Compounds and pharmaceutical uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-10-24 US disclosed
CN-115836062-A Compound and medical application thereof 心悦生医股份有限公司 2023-03-21 CN disclosed
US-20220218730-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2022-07-14 US disclosed
WO-2021046549-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2021-03-11 WO disclosed
US-8431378-B2 Aminotransferase, gene encoding the same, and methods of using them KANEKA CORPORATION (JP) 2013-04-30 US disclosed
US-20120164724-A1 NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM KANEKA CORPORATION (JP) 2012-06-28 US disclosed
US-8133705-B2 Aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2012-03-13 US disclosed
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2010-11-11 US disclosed
EP-1889907-B1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME KANEKA CORP (JP) 2009-09-02 EP disclosed
EP-1889907-A1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2008-02-20 EP disclosed
US-20060264653-A1 Aminoacetonitrile derivatives and their use for controlling parasites DUCRAY PIERRE 2006-11-23 US disclosed
US-7091371-B2 Aminoacetonitrile derivatives and their use for controlling parasites NOVARTIS ANIMAL HEALTH US, INC. (US) 2006-08-15 US disclosed
US-20050033081-A1 Aminoacetonitrile derivatives and their use for controlling parasites NOVARTIS AG (CH) 2005-02-10 US disclosed
EP-1456170-A1 AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES Novartis AG (CH) 2004-09-15 EP disclosed
WO-2003048112-A1 AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES NOVARTIS AG (CH) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218730-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF HRH4, OR10J3, CYP3A5 ALDH1A1 654/4885MAOB 1547/4885LMNA 4372/4885
US-20050033081-A1 Aminoacetonitrile derivatives and their use for controlling parasites NAT1, ALDH7A1, AAAS ALDH1A1 48/4885MAOB 1036/4885LMNA 2409/4885
US-20060264653-A1 Aminoacetonitrile derivatives and their use for controlling parasites AAAS, NAT1, ALDH7A1 ALDH1A1 74/4885MAOB 1027/4885LMNA 2402/4885
US-11793823-B2 Compounds and pharmaceutical uses thereof HRH4, OR10J3, CYP3A5 ALDH1A1 654/4885MAOB 1547/4885LMNA 4372/4885
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them BCAT1, AGXT, ALDH7A1 ALDH1A1 144/4885MAOB 1260/4885LMNA 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.